Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cellectar Biosciences, Inc. - Common Stock (NQ:CLRB)

3.180 -0.130 (-3.93%)
Streaming Delayed Price Updated: 9:57 AM EST, Feb 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cellectar Biosciences, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
Cellectar Biosciences Announces Pricing of $6 Million Underwritten Public Offering
From Cellectar Biosciences, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
 
Via Benzinga
News headline image
Cellectar Biosciences and U.S.-based Nusano Enter Into Multi-Isotope Supply Agreement
From Cellectar Biosciences, Inc.
Via GlobeNewswire
News headline image
Cellectar Biosciences Submits Phase 1b Clinical Trial Protocol to US Food and Drug Administration for CLR 125 to Treat Triple-Negative Breast Cancer (TNBC)
From Cellectar Biosciences, Inc.
Via GlobeNewswire
News headline image
Why Cheetah Mobile Shares Are Trading Higher By Over 11%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Top movers in Wednesday's after hours session ↗
After the conclusion of the US market's regular session on Wednesday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers. 
Via Chartmill
News headline image
Cellectar Biosciences Announces One-for-Thirty Reverse Stock Split
From Cellectar Biosciences, Inc.
Via GlobeNewswire
News headline image
Cellectar Biosciences Provides Update on CLOVER-2 Phase 1 Clinical Trial of Iopofosine I 131 in Pediatric Patients with Relapsed/Refractory High-Grade Glioma
In Patients Receiving a Minimum of 55 mCi an Average 5.4 Months of PFS was Observed: Twice the Reported 2.25 Median 
From Cellectar Biosciences, Inc.
Via GlobeNewswire
News headline image
The trading volume of these stocks is deviating from the norm in today's session. ↗
Let's have a look at what is happening on the US markets on Thursday. Below you can find the stocks with an unusual volume in today's session. 
Via Chartmill
News headline image
Which stocks are gapping on Thursday? ↗
Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Thursday. Let's explore the market movements and identify the stocks with significant gaps. 
Via Chartmill
News headline image
Cellectar Biosciences Enters into Common Stock Agreements to Raise $2.5 Million Priced at Market Under Nasdaq Rules
From Cellectar Biosciences, Inc.
Via GlobeNewswire
News headline image
Synergy CHC Corp. (NASDAQ: SNYR) Restructures Debt with $20M Facility to Power Global Growth and FOCUSfactor Beverage Expansion
Via AB Newswire
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
News headline image
Stay updated with the stocks that are on the move in today's after-hours session. ↗
As the regular session of the US market concludes on Wednesday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses. 
Via Chartmill
News headline image
What's going on in today's session ↗
Here are the top movers in Wednesday's session, showcasing the stocks with significant price changes. 
Via Chartmill
News headline image
Curious about the most active stocks on Wednesday? ↗
Stay updated with the latest market activity on Wednesday. Explore the most active stocks in today's session and stay informed about the stocks that are in the spotlight. 
Via Chartmill
News headline image
Crude Oil Falls Over 1%; ISM Services PMI Tumbles In May ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
What's Behind Cellectar Biosciences' Stock Surge? FDA Update Explained ↗
Cellectar's Iopofosine I 131 earned FDA breakthrough therapy designation for relapsed Waldenstrom macroglobulinemia following strong trial data. 
Via Benzinga
News headline image
Which stocks are experiencing notable movement on Wednesday? ↗
Curious to know what's happening on the US markets in the middle of the day on Wednesday? Join us as we explore the top gainers and losers in today's session. 
Via Chartmill
News headline image
US Stocks Higher; Dollar Tree Shares Plunge After Q1 Earnings ↗
 
Via Benzinga
News headline image
Wednesday's session: gap up and gap down stocks ↗
In today's session, there are notable price gaps in the US markets on Wednesday. Take a closer look at the stocks that are gap up and gap down. 
Via Chartmill
News headline image
Cellectar Granted U.S. FDA Breakthrough Therapy Designation for Iopofosine I 131 in Waldenstrom Macroglobulinemia (WM)
From Cellectar Biosciences, Inc.
Via GlobeNewswire
News headline image
Cellectar Biosciences Reports First Quarter 2025 Financial Results and Provides a Corporate Update
From Cellectar Biosciences, Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For May 13, 2025 ↗
 
Via Benzinga
News headline image
Insights Ahead: Cellectar Biosciences's Quarterly Earnings ↗
 
Via Benzinga
News headline image
Cellectar Biosciences to Report First Quarter Financial Results and Host a Conference Call on Tuesday, May 13, 2025
From Cellectar Biosciences, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
Cellectar Announces Plan to Explore Strategic Alternatives
From Cellectar Biosciences, Inc.
Via GlobeNewswire
News headline image
Cellectar Biosciences Reports Financial Results for Year Ended 2024 and Provides a Corporate Update
From Cellectar Biosciences, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.